Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in Sweden

Abstract

Deutsche Krebshilfe, Jane and Aatos Erkko Foundation, Sigrid Juselius Foundation, Finnish Cancer Organizations, Swedish Research Council, ALF from Region Skåne, and Bloodwise.

Second cancers in MPN: Survival analysis from an international study

“…9 The risk of second primary malignancies is particularly high in patients with primary lymphoid neoplasms, 9 but is also significantly increased in myeloid neoplasms. 5 The genetic basis of multiple primary cancers is not well-known, however, the JAK2V617F mutation was associated with both solid and lymphoid neoplasms, and the rs2736100_C SNP of TERT has been proved to increase the risk of solid cancers in MPN patients. 5 The genetic basis of multiple primary cancers is not well-known, however, the JAK2V617F mutation was associated with both solid and lymphoid neoplasms, and the rs2736100_C SNP of TERT has been proved to increase the risk of solid cancers in MPN patients.…”

“…5 In particular, cancers in the upper gastrointestinal tract, nose, lung, kidney, skin, endocrine gland and nervous system are significantly increased in MPN patients as compared with the general population. 5 The genetic basis of multiple primary cancers is not well-known, however, the JAK2V617F mutation was associated with both solid and lymphoid neoplasms, and the rs2736100_C SNP of TERT has been proved to increase the risk of solid cancers in MPN patients. [10][11][12][13][14][15] However, we investigated also further hypotheses for ruxolitinib, since the association with survival was impressive.…”

“…[1][2][3][4][5] Blood and solid cancers occur in about 17% of patients with MPN, often preceding the diagnosis of MPN: melanoma, prostate cancer and non-MPN blood cancers have been diagnosed in excess as compared with control population in North Europe registry studies. In addition to these incident events, recent studies consistently reported that MPN patients are also prone to an increased risk of developing second cancers (SC).…”

“…In addition to these incident events, recent studies consistently reported that MPN patients are also prone to an increased risk of developing second cancers (SC). [1][2][3][4][5] Blood and solid cancers occur in about 17% of patients with MPN, often preceding the diagnosis of MPN: melanoma, prostate cancer and non-MPN blood cancers have been diagnosed in excess as compared with control population in North Europe registry studies. 6 We recently published the results from a nested case-control study with 647 MPN patients with SC and 1234 matched controls (MPN patients without SC) recruited from European LeukemiaNet (ELN) centers and reported that the exposure to cytoreductive drugs, such as hydroxyurea and ruxolitinib, increases the occurrence of nonmelanoma skin cancers.…”

Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia

“…Even though many studies have published the risks of SPC after CLL and some have been published after HCL, no previous studies have analysed the risks of leukaemias as SPC. The bi‐directional analysis was recently applied for myeloid neoplasms and NHL in providing evidence for reciprocal relationships between cancer risks (Chattopadhyay et al , ,). The findings from bi‐directional analyses may give insight concerning the mechanisms of SPC, particularly on the contribution of the adverse consequence of therapy, as therapies are rarely identical for two cancers.…”